Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention

Category	Detail
Condition	Breast Cancer
Key Mechanisms	Gut microbiota alterations and serum metabolomic changes associated with breast cancer progression and chemotherapy response.
Target Population	Female participants with benign breast disease, breast cancer, and postchemotherapy breast cancer.
Care Setting	Clinical research setting.

Significant shifts in gut microbiota from benign breast disease to breast cancer and postchemotherapy.
Identification of potential biomarkers for distinguishing disease stages and chemotherapy responses.
Dynamic remodeling of serum metabolomic profiles throughout disease progression and treatment.
Integration of multiomics data reveals systemic shifts in gut–metabolism interaction patterns.
Establishment of a multiomics classification model with high efficacy in distinguishing between disease stages.

Utilize gut microbiota and serum metabolomic profiles for differential diagnosis of breast disease stages.

Consider microbiome-targeted therapies and metabolic profiling in breast cancer management.

Monitor changes in gut microbiota and serum metabolites for assessing treatment response.

Be aware of the transition from a protective microbiome state to an inflammatory/pathogenic state during disease progression.

Female patients with benign breast disease, breast cancer, and those undergoing chemotherapy.

Potential for microbiome and metabolomic profiling to guide personalized treatment strategies.

Incorporate multiomics approaches in clinical assessments of breast cancer.
Evaluate gut microbiota diversity as part of the diagnostic process.
Utilize identified metabolites as biomarkers for monitoring disease progression and treatment efficacy.

Clinical Scorecard: Shifts in Gut Microbiota and Serum Metabolites: Clinical Implications for Breast Cancer Development, Progression, and Chemotherapy Response